about
Changes in function of HIV-specific T-cell responses with increasing time from infection.Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite ControllersAntiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeHIV-associated lipodystrophy syndrome: A review of clinical aspects.Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness.Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection.Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection.Socio-economic status and time trends associated with early ART initiation following primary HIV infection in Montreal, Canada: 1996 to 2015.[Treatment of HIV marginalized patients: an approach to documenting medical and psychosocial appointments of patients with problematic drug use].Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.
P50
Q34142433-8A05DC9F-F9E7-4242-B7D0-2E886F127E5DQ35077002-212B469B-0587-4989-86B7-007432EAF8D8Q35090639-1BAF4DA4-00C4-4E46-AFC8-9231CDC93F02Q35124959-40CAB112-ABD5-4769-ABD9-CCE339CC8C98Q36171069-BB7AA4FD-46F1-428F-929D-E182212AC04CQ36402487-8456730C-74C2-47B0-AF1D-FA76E4C6B2C3Q36676374-D64E72C9-BF96-46A7-B17F-911DE3627667Q36871125-5FCE0AA7-3C49-4073-B850-FA660897EAB2Q37525649-16D02CA1-2E72-4733-8867-8A4A94DF8A4FQ40328514-5C1CDBE9-45DD-46DE-AA24-BD8EEFF58B11Q41914803-706B9D3F-1910-4390-9722-D04EF9BAB456Q43541636-1E36BC29-4E4F-4FD2-A47D-B55A6EBED2E7Q45733147-D25A1AB5-4B47-4691-B3A4-69B7434AAD55Q48089349-8486BDD5-7961-4487-99AD-EA17A302E556Q52296105-16154017-772E-44DB-B8DA-D1C51C84A33BQ53878001-027EFA2D-3D75-4F7B-B796-9CF25273F75D
P50
description
HIV researcher
@en
name
Pierre Côte
@sq
Pierre Côté
@ast
Pierre Côté
@en
Pierre Côté
@es
Pierre Côté
@fr
Pierre Côté
@ga
Pierre Côté
@nl
Pierre Côté
@sl
type
label
Pierre Côte
@sq
Pierre Côté
@ast
Pierre Côté
@en
Pierre Côté
@es
Pierre Côté
@fr
Pierre Côté
@ga
Pierre Côté
@nl
Pierre Côté
@sl
prefLabel
Pierre Côte
@sq
Pierre Côté
@ast
Pierre Côté
@en
Pierre Côté
@es
Pierre Côté
@fr
Pierre Côté
@ga
Pierre Côté
@nl
Pierre Côté
@sl